Patents by Inventor Yewei JI

Yewei JI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions to treat type-1 and type-2 diabetes
    Patent number: 9957287
    Abstract: The present disclosure is directed to novel methods of treating type-1 or type-2 diabetes by inactivating TLR2 and TLR4 genes together in cells capable of producing insulin and/or regenerating ? cells, and providing the cells to a subject in need thereof.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: May 1, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Ling Qi, Shengyi Sun, Yewei Ji
  • METHODS AND COMPOSITIONS TO TREAT TYPE-1 AND TYPE-2 DIABETES
    Publication number: 20170342097
    Abstract: The present disclosure is directed to novel methods of treating type-1 or type-2 diabetes by inactivating TLR2 and TLR4 genes together in cells capable of producing insulin and/or regenerating ? cells, and providing the cells to a subject in need thereof.
    Type: Application
    Filed: May 24, 2017
    Publication date: November 30, 2017
    Inventors: Ling QI, Shengyi SUN, Yewei JI
  • Method to screen for an activator of adipose-resident NK cells
    Patent number: 9623083
    Abstract: Obesity is associated with a state of chronic low-grade inflammation and the present invention establishes that adipose-resident natural killer T (NKT) cells attenuate inflammation in adipose tissue and improves systemic glucose homeostasis in mice at different stages of obesity. Accordingly, the present invention provides methods of treating type-2 diabetes or those at risk for type-2 diabetes using activators of adipose-resident NKT cells. Such activators include particular glycolipids (e.g., a-galactosylceramide and its analogs other than sulfated analogs) and cytokines that promote M2 macrophage polarization. The invention also includes methods to screen for activators of adipose-resident NKT cells.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: April 18, 2017
    Assignee: Cornell University
    Inventors: Ling Qi, Yewei Ji
  • SYSTEMIC GLUCOSE TOLERANCE IN TYPE-2 DIABETES
    Publication number: 20140193361
    Abstract: Obesity is associated with a state of chronic low-grade inflammation and the present invention establishes that adipose-resident natural killer T (NKT) cells attenuate inflammation in adipose tissue and improves systemic glucose homeostasis in mice at different stages of obesity. Accordingly, the present invention provides methods of treating type-2 diabetes or those at risk for type-2 diabetes using activators of adipose-resident NKT cells. Such activators include particular glycolipids (e.g., a-galactosyl-ceramide and its analogs other than sulfated analogs) and cytokines that promote M2 macrophage polarization. The invention also includes methods to screen for activators of adipose-resident NKT cells.
    Type: Application
    Filed: August 30, 2012
    Publication date: July 10, 2014
    Applicant: CORNELL UNIVERSITY
    Inventors: Ling Qi, Yewei JI